Welcome to our dedicated page for Greater Cannabis news (Ticker: GCAN), a resource for investors and traders seeking the latest updates and insights on Greater Cannabis stock.
The Greater Cannabis Company develops cannabinoid therapeutics as a clinical-stage biopharmaceutical issuer trading under GCAN. Company news centers on cannabinoid-based medical research, including neuropsychiatric programs, autism spectrum disorder studies, preclinical work, clinical-trial approvals, and licensed therapeutic development.
Updates also cover GCANRx's public-company status, including OTC market-tier changes, reporting and compliance positioning, and other capital-markets communications. The company's recurring disclosures connect its cannabis-based treatment focus with clinical research activity and its efforts to maintain quotation and visibility in the over-the-counter market.
Greater Cannabis Company (GCAN) has entered a licensing agreement with Shaare Zedek Scientific Ltd. for a novel cannabinoid therapy aimed at treating autism, schizophrenia, and other neuropsychiatric disorders. This partnership includes a joint research development initiative led by Dr. Adi Aran from Shaare Zedek Medical Center, known for its extensive clinical research. Dr. Aran’s previous studies demonstrated significant improvements in behavioral issues for autistic children using cannabis-based therapies.
The Greater Cannabis Company (OTCQB: GCAN) has announced a collaboration with Israel's Phytor LTD to develop cannabinoid and botanical-based therapeutics targeting dermatological and chronic ailments. Led by Dr. Yehoshua Maor, Phytor is recognized for its expertise in plant-based therapeutics. This partnership aims to create more effective, natural solutions that can provide rapid relief compared to conventional treatments. Both companies will integrate their technologies to enhance product offerings for consumer and commercial use.
The Greater Cannabis Company (OTCQB: GCAN) announced the reinstatement of its common stock for trading on the OTCQB Venture Market after a compliance review. This upgrade reflects adherence to high financial standards and improved corporate governance, which the Company believes will enhance investor benefits.
The move is expected to increase transparency, reporting standards, and liquidity, as the OTCQB is viewed as an established public market by the SEC. This tier is known to improve awareness and analyst coverage for companies.
Greater Cannabis Co. (OTC: GCAN) announced that CEO Aitan Zacharin will present at the Benzinga Virtual Cannabis Investor Conference on February 26th at 10:35 AM EST. The presentation will last approximately 20 minutes and will cover an overview of the company's business, technology, and recent progress. GCAN encourages both individual and institutional investors to attend using a free spectator pass available online.
The company specializes in developing innovative cannabinoid delivery systems aimed at enhancing patient experience and efficacy.